Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ATRC 
AtriCure Inc (ATRC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ATRC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -32.38% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.67B USD | Price to earnings Ratio - | 1Y Target Price 52.22 |
Price to earnings Ratio - | 1Y Target Price 52.22 | ||
Volume (30-day avg) 606589 | Beta 1.54 | 52 Weeks Range 18.94 - 43.11 | Updated Date 04/2/2025 |
52 Weeks Range 18.94 - 43.11 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.95 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -9.61% | Operating Margin (TTM) -11.69% |
Management Effectiveness
Return on Assets (TTM) -4.09% | Return on Equity (TTM) -9.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1584432589 | Price to Sales(TTM) 3.59 |
Enterprise Value 1584432589 | Price to Sales(TTM) 3.59 | ||
Enterprise Value to Revenue 3.41 | Enterprise Value to EBITDA -135.97 | Shares Outstanding 48879600 | Shares Floating 47154643 |
Shares Outstanding 48879600 | Shares Floating 47154643 | ||
Percent Insiders 3.49 | Percent Institutions 98.58 |
Analyst Ratings
Rating 4.56 | Target Price 45.11 | Buy 4 | Strong Buy 5 |
Buy 4 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
AtriCure Inc
Company Overview
History and Background
AtriCure, Inc. was founded in 2000. The company develops, manufactures, and sells medical devices for the treatment of atrial fibrillation (Afib) and related conditions. Its focus is on surgical ablation solutions.
Core Business Areas
- Cardiac Ablation: Develops and markets devices for surgical ablation, primarily for treating atrial fibrillation. Includes radiofrequency ablation and cryoablation technologies.
- Left Atrial Appendage Management: Offers devices for the LAA occlusion in patients with AFib to reduce the risk of stroke.
- Pain Management: Products to manage post-operative pain following thoracic procedures
Leadership and Structure
Michael Carrel is the CEO. The company has a board of directors overseeing its strategic direction. It operates with functional departments including R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- AtriClip LAA Exclusion System: A device used to occlude the left atrial appendage in patients with atrial fibrillation, reducing the risk of stroke. AtriCure estimates they have a ~65% market share in the LAA exclusion market. Competitors include Boston Scientific (WATCHMAN device) and Abbott (AMULET device).
- CryoICE Cryoablation System: A cryoablation system used to create lesions on the heart to block irregular electrical signals that cause atrial fibrillation. No specific revenue available. Medtronic and Biosense Webster are competitors.
- Isolator Synergy Ablation System: A bipolar radiofrequency ablation system used to create lesions on the heart to block irregular electrical signals that cause atrial fibrillation. No specific revenue available. Medtronic and Biosense Webster are competitors.
- Epi-Sense System: A surgical ablation system. No specific revenue available. Medtronic and Biosense Webster are competitors.
Market Dynamics
Industry Overview
The cardiac ablation market is growing, driven by the increasing prevalence of atrial fibrillation, technological advancements, and a growing aging population. Surgical ablation is a significant segment within this market.
Positioning
AtriCure is a leading player in the surgical ablation market, particularly in LAA management. Its strengths lie in its specialized focus, innovative products, and established presence in cardiac surgery.
Total Addressable Market (TAM)
Estimates vary, but the global cardiac ablation market is projected to reach billions of dollars. AtriCure is well-positioned to capture a significant portion of this market, particularly in surgical ablation and LAA management, which it estimates to be $8 billion.
Upturn SWOT Analysis
Strengths
- Leading position in surgical ablation market
- Strong brand recognition in cardiac surgery
- Innovative product portfolio
- Established sales and distribution network
- Focus on atrial fibrillation treatment
Weaknesses
- Reliance on surgical procedures
- Limited presence in non-surgical ablation market
- High dependence on key products
- Profitability and margin challenges
- Smaller scale compared to larger competitors
Opportunities
- Expanding into adjacent markets (e.g., pain management)
- Developing minimally invasive ablation technologies
- Increasing adoption of LAA management procedures
- Geographic expansion, particularly in emerging markets
- Strategic acquisitions and partnerships
Threats
- Competition from larger medical device companies
- Reimbursement pressures and healthcare reforms
- Technological advancements in non-surgical ablation
- Clinical trial risks and regulatory hurdles
- Economic downturns impacting hospital budgets
Competitors and Market Share
Key Competitors
- MDT
- JNJ
- BSX
- ABT
Competitive Landscape
AtriCure's advantage lies in its specialized focus and established presence in cardiac surgery. However, it faces intense competition from larger, more diversified medical device companies. AtriCure must continue to innovate and execute effectively to maintain its market position.
Major Acquisitions
SentreHEART, Inc
- Year: 2021
- Acquisition Price (USD millions): 300
- Strategic Rationale: To expand its LAA management portfolio with SentreHEART's percutaneous LAA closure technology.
Growth Trajectory and Initiatives
Historical Growth: AtriCure has experienced revenue growth driven by increased adoption of its ablation and LAA management products. However, profitability has been a challenge.
Future Projections: Analysts expect continued revenue growth for AtriCure, driven by the increasing prevalence of atrial fibrillation and the adoption of its products. Profitability is expected to improve over time.
Recent Initiatives: Focus on expanding sales force, product innovation (e.g., next-generation ablation technologies), and strategic acquisitions (see Acquisitions section).
Summary
AtriCure is a strong player in the surgical ablation and LAA management markets, driven by its focused strategy and innovative product portfolio. However, it faces competition from larger medical device companies and needs to improve profitability. Future growth depends on successful product launches, strategic acquisitions, and expansion into new markets. Maintaining a technological edge is critical.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MDT
Medtronic PLC
MDT
Medtronic PLC
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary. Financial data may be outdated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AtriCure Inc
Exchange NASDAQ | Headquaters Mason, OH, United States | ||
IPO Launch date 2005-08-05 | CEO, President & Director Mr. Michael H. Carrel | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1300 | Website https://www.atricure.com |
Full time employees 1300 | Website https://www.atricure.com | ||
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.